Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Headache and Pain|April 24, 2015
Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorderNoboru Imai, Noriko Miyake, Yoshiaki Saito, et al.
Cureus|April 25, 2024
Headache-Related Characteristics of Biopsy-Confirmed Giant Cell Arteritis and the Relationship of Transmural Inflammation With Artery Tenderness and Chordal ThickeningSho Shimohama, Noboru Imai, Takuya Tsubata, et al.
Headache|June 21, 2021
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled studyTakao Takeshima, Fumihiko Sakai, Koichi Hirata, et al.
Expert Opinion on Drug Safety|December 29, 2022
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at homeKoichi Hirata, Takao Takeshima, Noboru Imai, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 5, 2023
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative reviewTsubasa Takizawa, Keiko Ihara, Shunsuke Uno, et al.
The Journal of Headache and Pain|September 19, 2021
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trialKoichi Hirata, Fumihiko Sakai, Takao Takeshima, et al.
Forensic Science International|March 27, 2012
Development of heavy mineral and heavy element database of soil sediments in Japan using synchrotron radiation X-ray powder diffraction and high-energy (116 keV) X-ray fluorescence analysis: 1. Case study of Kofu and Chiba regionWilly Shun Kai Bong, Izumi Nakai, Shunsuke Furuya, et al.
Headache|July 29, 2021
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patientsFumihiko Sakai, Norihiro Suzuki, Byung-Kun Kim, et al.
The Journal of Headache and Pain|March 16, 2024
CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache societyTsubasa Takizawa, Keiko Ihara, Narumi Watanabe, et al.
Brain and Behavior|February 24, 2022
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studiesKoichi Hirata, Takao Takeshima, Fumihiko Sakai, et al.
Pageof 5